BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma

Phase 2

Completed

Conditions: Renal Cell Carcinoma

Interventions: Biological: Opdivo
Biological: Yervoy

First Posted Date: 2017-01-24

Last Posted Date: 2022-06-29

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 104

Registration Number: NCT03029780

Locations: 🇨🇱
Centro Internacional de Estudios Clinicos, Recoleta, Santiago De Chile, Chile
🇨🇱
Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile
🇺🇸
Levine Cancer Institute, Charlotte, North Carolina, United States

and more 3 locations

Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure

Phase 2

Completed

Conditions: Heart Failure

Interventions: Drug: HNO Donor
Drug: Placebo

First Posted Date: 2017-01-10

Last Posted Date: 2021-01-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 329

Registration Number: NCT03016325

Locations: 🇺🇸
DMC Detroit Receiving Hospital, Detroit, Michigan, United States
🇺🇸
Henry Ford Health System, Detroit, Michigan, United States
🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States

and more 22 locations

Pharmacokinetics and Metabolism of [14C]BMS-986165 in Healthy Male Participants

Phase 1

Completed

Conditions: Psoriasis

Interventions: Drug: BMS-986165

First Posted Date: 2016-12-29

Last Posted Date: 2018-02-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 6

Registration Number: NCT03004768

Locations: 🇺🇸
Covance Madison Clinical Research Unit, Madison, Wisconsin, United States

Bleeding Events and Oral Anticoagulant Treatment in Non-Valvular Atrial Fibrillation

Withdrawn

Conditions: Non-valvular Atrial Fibrillation

First Posted Date: 2016-12-26

Last Posted Date: 2018-10-10

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT03002740

An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Biological: Nivolumab
Biological: Ipilimumab

First Posted Date: 2016-12-23

Last Posted Date: 2024-05-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 230

Registration Number: NCT03001882

Locations: 🇮🇹
Local Institution - 0026, Parma, Italy
🇮🇹
Local Institution - 0024, Perugia, Italy
🇳🇱
Local Institution - 0021, Amsterdam, Netherlands

and more 32 locations

A Study to Evaluate Safety of Single Doses of BMS-986177 in Patients With End Stage Renal Disease (ESRD) Treated With Hemodialysis

Phase 1

Completed

Conditions: Antithrombotic

Interventions: Drug: Enoxaparin
Drug: unfractionated heparin (UFH)
Drug: BMS-986177

First Posted Date: 2016-12-22

Last Posted Date: 2020-12-29

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 32

Registration Number: NCT03000673

Locations: 🇺🇸
Davita Clinical Research, Minneapolis, Minnesota, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)

Phase 3

Active, not recruiting

Conditions: Non Small Cell Lung Cancer

Interventions: Biological: Nivolumab
Drug: Cisplatin
Drug: Vinorelbine
Biological: Ipilimumab
Drug: Gemcitabine
Drug: Docetaxel
Drug: Pemetrexed
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2016-12-20

Last Posted Date: 2023-10-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 505

Registration Number: NCT02998528

Locations: 🇺🇸
Memorial Regional Hospital, Hollywood, Florida, United States
🇺🇸
Local Institution - 0151, Baltimore, Maryland, United States
🇺🇸
Local Institution - 0006, Boston, Massachusetts, United States

and more 132 locations

A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma

Phase 2

Completed

Conditions: Advanced Cancer

Interventions: Biological: Nivolumab
Biological: Ipilimumab
Biological: Relatlimab
Drug: BMS-986205
Drug: BMS-813160

First Posted Date: 2016-12-19

Last Posted Date: 2022-12-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 182

Registration Number: NCT02996110

Locations: 🇦🇹
Local Institution - 0044, Linz, Oberösterreich, Austria
🇺🇸
Local Institution - 0043, Charlotte, North Carolina, United States
🇺🇸
Local Institution - 0007, Baltimore, Maryland, United States

and more 27 locations

Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab Therapy

Active, not recruiting

Conditions: Melanoma

First Posted Date: 2016-12-13

Last Posted Date: 2022-04-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1087

Registration Number: NCT02990611

Locations: 🇩🇪
Local Institution, Essen, Germany

A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Biological: Ipilimumab
Biological: Nivolumab
Drug: Cabazitaxel
Drug: Prednisone

First Posted Date: 2016-12-07

Last Posted Date: 2024-05-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 351

Registration Number: NCT02985957

Locations: 🇺🇸
Local Institution - 0078, Albany, New York, United States
🇺🇸
Local Institution - 0010, Philadelphia, Pennsylvania, United States
🇩🇰
Local Institution - 0063, Aarhus N, Midtjylland, Denmark

and more 56 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy